Alzheimer’s Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid Biomarkers: Difference in Cut-Off Levels from Thai Experience

Table 2

Results mean (SD) of CSF A𝛽 1–42, tTau, pTau, and pTau/A𝛽 1–42 in 3 groups of the study.

Group/CSF	CSF A𝛽 1–42 (pg/mL)	CSF tTau (pg/mL)	CSF pTau (pg/mL)	CSF pTau/A𝛽 1–42
AD (𝑛=14)	241.36 (60.14)	222.79 (212.24)	40.79 (27.84)	0.1807 (0.1218)
Non-AD dementia (𝑛=10)	430.40 (125.18)	349.30 (692.16)	36.80 (14.90)	0.0914 (0.0423)
Noncases (𝑛=4)	499.75 (93.44)	137.25 (62.74)	31.75 (17.48)	0.0617 (0.0238)
P value (ANOVA)	𝑃<0.0001^*	𝑃=0.672	𝑃=0.767	𝑃=0.028^*
Post hoc; ^*𝑃<0.05	AD versus non-AD^* AD versus noncases^* Non-AD versus noncases	—	—	AD versus non-AD (𝑃=0.060); AD versus noncases^*; Non-AD versus noncases

CSF: Cerebrospinal fluid.
A𝛽1-42: Beta amyloid 1-42.
AD: Alzheimer’s disease.